

Kurt A. Jellinger

P25 α immunoreactivity in multiple system atrophy and Parkinson disease

Received: 11 April 2006 / Accepted: 11 April 2006 / Published online: 11 May 2006
© Springer-Verlag 2006

Recently, Baker et al. [1] reported p25 α and α -synuclein reactivity in glial cytoplasmic inclusions (GCI) in oligodendroglia of multiple system atrophy (MSA) but p25 α immunoreactivity in neuronal cytoplasmic inclusions (NCI) co-localized with α -synuclein labeling in only about 40%. These data can be largely confirmed by own studies in two cases each of MSA and Parkinson disease (PD), using formalin-fixed, paraffin-embedded slides and routine peroxidase immunohistochemistry for α -synuclein (monoclonal and polyclonal antibodies, Chemicon, Temecula, CA, USA) and p25 α (purified polyclonal rabbit anti IgG, diluted 1:200 and 1:1000; gift of Prof. P. H. Jensen, Department of Medical Biochemistry, University of Aarhus, Denmark).

In MSA, anti-p25 α labeled many GCI in oligodendroglia, virtually identical in localization and intensity with α -synuclein immunoreactivity, whereas it did not stain normal oligodendroglia [4]. In MSA, anti-p25 α labeled only part of NCIs, virtually all of them being negative for α -synuclein [3].

In PD, the vast majority of cortical Lewy bodies showing intense α -synuclein immunoreactivity were negative for p25 α , whereas subcortical Lewy bodies, consistently positive for α -synuclein, showed inconsistent p25 α immunoreactivity.

While p25 α -positive subcortical Lewy bodies in PD showed rather diffuse appearance, in MSA p25 α -positive NCIs often displayed a punctate appearance of immunoreactive structures, as described by Baker et al. [1], suggesting that protein aggregation may occur, although p25 α is folded and flexible without overt tendency for aggregation [5]. Brain-specific p25 α was identified as a candidate that preferentially binds α -synuclein in its aggregated state [4]. Since p25 α shares the property of

heat stability with the aggregation-prone proteins tau and α -synuclein [4], these properties and the abnormal location of p25 α suggest that aggregation of both p25 α and tau-protein probably induced by additional co-factors may impair neuronal function, as suggested recently for Alzheimer disease (AD) neurons, showing co-localization of p25 α and tau-positive pretangle structures [3], but not in other tauopathies. Since p25 α -immunopositive neurons in both MSA and AD ultrastructurally show “twisted” and “straight” filaments [6], its abnormal expression may occur in a variety of neuronal types in diverse neurodegenerative disorders, in particular synucleinopathies, and may indicate some synergistic reaction with α -synuclein, as has been suggested for α -synuclein and tau [2, 7], which may also occur in PD.

References

1. Baker KG, Huang Y, McCann H, Gai WP, Jensen PH, Halliday GM (2006) P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. *Acta Neuropathol (Berl)* 111:193–195
2. Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. *Ann Neurol* 59:449–458
3. Kovacs GG, Laszlo L, Kovacs J, Jensen PH, Lindersson E, Botond G, Molnar T, Perczel A, Hudecz F, Mezo G, Erdei A, Tirian L, Lehotzky A, Gelpi E, Budka H, Ovadi J (2004) Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. *Neurobiol Dis* 17:155–162
4. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH (2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers. *J Biol Chem* 279:12924–12934
5. Otzen DE, Lundvig DM, Wimmer R, Nielsen LH, Pedersen JR, Jensen PH (2005) p25alpha is flexible but natively folded and binds tubulin with oligomeric stoichiometry. *Protein Sci* 14:1396–1409
6. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. *Neurosci Lett* 251:205–208
7. Wenning GK, Jellinger KA (2005) The role of alpha-synuclein and tau in neurodegenerative movement disorders. *Curr Opin Neurol* 18:357–362

K. A. Jellinger (✉)
Institute of Clinical Neurobiology,
Kenyongasse 18, 1070 Vienna, Austria
E-mail: kurt.jellinger@univie.ac.at
Tel.: +43-1-5266534
Fax: +43-1-5238634